Article

Anti-HVEM mAb therapy improves antitumoral immunity both <i>in vitro</i> and <i>in vivo</i> , in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

2022-11-05

Abstract excerpt

<h4>Background</h4> TNFRF-14/HVEM is the ligand for BTLA and CD160 negative immune co-signaling molecules as well as viral proteins. Its expression is dysregulated with an overexpression in tumors and a connection with tumors of adverse prognosis. <h4>Methods</h4> We developed C57BL/6 mouse models co-expressing human huBTLA and huHVEM as well as antagonistic monoclonal antibodies (mAbs) that completely prevent t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 079e199a-b651-5a8b-8028-89cb1da4d739
DOI: 10.1101/2022.11.04.515180

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anti-HVEM mAb therapy improves antitumoral immunity both <i>in vitro</i> and <i>in vivo</i> , in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumorsDOI 10.1101/2022.11.04.515180Read

TNFRSF14 (HVEM) is a novel immune checkpoint for cancer immunotherapy in humanized miceSemantic proximity Read

HVEM is a Novel Immune Checkpoint for Prostate Cancer Immunotherapy in Humanized MiceSemantic proximity Read

Targeting HVEM-GPT2 axis: a novel approach to T cell activation and metabolic reprogramming in non-small cell lung cancer therapySemantic proximity Read

Inhibition of HVEM suppresses growth and invasion of mesenchymal glioblastomaSemantic proximity Read

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEMSemantic proximity Read

New mouse model based on adenocarcinoma 4T1 cells expressing HPV16 E6 and E7 applied to assess the efficacy of therapeutic and prophylactic E6/E7-based HPV16 vaccinesSemantic proximity Read

Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interactionSemantic proximity Read

Modified Hypoxia Inducible Factor expression in CD8+ T cells increases anti-tumor efficacySemantic proximity Read

HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160Semantic proximity Read

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.Semantic proximity Read

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.Semantic proximity Read

HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.Semantic proximity Read